Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $37.1 million.

  • Eton Pharmaceuticals' Cash & Equivalents rose 8321.41% to $37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year increase of 8321.41%. This contributed to the annual value of $14.9 million for FY2024, which is 3016.64% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Cash & Equivalents stood at $37.1 million, which was up 8321.41% from $25.4 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Cash & Equivalents ranged from a high of $37.1 million in Q3 2025 and a low of $13.4 million during Q3 2022
  • Over the past 5 years, Eton Pharmaceuticals' median Cash & Equivalents value was $17.7 million (recorded in 2024), while the average stood at $20.0 million.
  • In the last 5 years, Eton Pharmaceuticals' Cash & Equivalents surged by 20972.45% in 2021 and then plummeted by 4108.94% in 2022.
  • Eton Pharmaceuticals' Cash & Equivalents (Quarter) stood at $14.4 million in 2021, then increased by 13.18% to $16.3 million in 2022, then surged by 31.17% to $21.4 million in 2023, then crashed by 30.17% to $14.9 million in 2024, then soared by 148.53% to $37.1 million in 2025.
  • Its last three reported values are $37.1 million in Q3 2025, $25.4 million for Q2 2025, and $17.4 million during Q1 2025.